Dr. Tom Colletti
Purpose: The purpose of this article is to review literature discussing the treatment of early Covid-19 infection with mABs and the data indicating reductions in hospitalization, morbidity, and mortality.
Method: A PubMed literature search was conducted utilizing the search terms neutralizing monoclonal antibodies, monoclonal antibodies to treat Covid-19, monoclonal antibodies reduce hospitalization, monoclonal outcomes to prevent hospitalization.
Results: Covid-19 disease is a recently discovered illness therefore large, well-controlled in- vivo studies following patients after IV treatment with monoclonal antibodies have been utilized to treat multiple illnesses are few. Studies also only followed patients who meet strict co-morbid condition criteria for multiple co-morbid conditions. Adding to the study challenges, treatment is expensive, and the FDA’s Emergency Use Act only offered payment for the treatment well into the first year of the pandemic. Despite the paucity of data, few multiple large, well-controlled, and authored studies, including a 3 state Mayo Clinic study, the treatment is effective.1 Early identification of qualified patients, and timely utilization of mABs treatment, was very well tolerated, reduced hospital admissions, morbidity, intubations, and mortality in adults over 35.1,2
Keywords: Covid-19, SARS-CoV-2 virus, monoclonal antibody treatment, neutralizing monoclonal antibodies.
Luongo AA. Early Treatment with Monoclonal Antibodies Reduces Covid-19 Hospitalizations. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.